20
Participants
Start Date
April 11, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
Dextenza 0.4Mg Ophthalmic Insert
This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
topical prednisolone acetate 1% (PredForte) eye drops
The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
Mission Bay Hospital, San Francisco
UCSF Pediatric Ophthalmology, San Francisco
Wayne and Gladys Center for Vision, San Francisco
Maanasa Indaram, MD
OTHER